Heart-Type Fatty Acid-Binding Protein in the Early Diagnosis of Acute Myocardial Infarction:The potential for influencing patient management by Alhadi, Hafidh A & Fox, Keith A A
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Heart-Type Fatty Acid-Binding Protein in the Early Diagnosis of
Acute Myocardial Infarction
Citation for published version:
Alhadi, HA & Fox, KAA 2010, 'Heart-Type Fatty Acid-Binding Protein in the Early Diagnosis of Acute
Myocardial Infarction: The potential for influencing patient management' Sultan Qaboos University Medical
Journal, vol. 10, no. 1, pp. 41-9.
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Early version, also known as pre-print
Published In:
Sultan Qaboos University Medical Journal
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
SQU Med J, April 2010, Vol. 10, Iss. 1, pp. 41-49, Epub. 17th Apr 10
Submitted 28th June 09
Revision Req. 24th Oct 09, Revision Recd. 1st Nov 09
Accepted 3rd Jan 10
1Department of Medicine, Sultan Qaboos University Hospital, Muscat, Oman; 2University of Edinburgh Cardiovascular Research 
Unit, Royal Infirmary of Edinburgh, UK 
To whom correspondence should be addressed. E-mail: halhadi@hotmail.com
 في بيلقلا عونلا - نيهدلا ضمحلل طبارلا ينتوبرلا رود
ةدالحا ةيبلقلا ةطلجلل ّركبلما صيخشتلا
ضيرلما جلاع في يرثأتلا ةيناكما
س�ك�ف ثيكو يداهلا ظفاح
 ملاآ نم نوناعي نيذلا ىضرلما دنع ةيبلقلا ةطلجلل ركبلما صيخشتلا ىلع يبلقلا عونلا – ينهدلا ضمحلل طبارلا ينتوربلا ةردق ةسارد :فدهلا :صخللما
 ةداح ةيردص ملآآب ئراوطلا قيرط نع اولخُدا ةبقاعتم ةلاح ةئلم ةيقابتسا ةسارد تيرجأ :ةقيرطلا .ةيسايقلا ةيبلقلا تامصاولا عم اهتنراقمو ردصلا يف ةداح
 ضمحلل طبارلا ينتوربلاو ،ينبولجويام ،(ب م) ينتايركلا زينياك ةلتك ،(ت) بلقلا يننوبورت  ،(آ ) بلقلا يننوبورت زيكرت سايق تم .ةيبلق ةطلج دوجول رشؤمك
 ةجيتنلا سايقم .ضيرلما لوصو نم ةعاس 24-16 و ،ةعاس 10-8 ينبو ،تاعاس 4 و ينتعاس دعبو ،ئراوطلل لوصولا دنع ةرشابم يبلقلا عونلا – ينهدلا
 عونلا – ينهدلا ضمحلل طبارلا ينتوربلا زيكرت ةورذ نأ جئاتنلا ترهظأ :جئاتنلا .ملالآا عوقو نم تاعاس 6 للاخ سسحتلل ةجيتن لضفأ سايق وه ةيسيئرلا
 لدعم ىلع لصح ثيح ،نيرخلآاب ةنراقم ةيبلق ةطلج دوجو ىلع ركبم مصاو لضفأ ناكو ،ردصلا ملاآب ساسحلإا ةيادب نم تاعاس 8 دعب لصح يبلقلا
 ىرخلأا تامصاولا ةيساسح تناك  .يلاوتلا ىلع ينتعاس دعبو ئراوطلل مهلوصو ينح ةيبلق ةطلجب ينباصلما ىضرلما دنع (98% و 79.9%) ةبسنب سستح
 ينتوربلل ةيبلسلا ةيؤبنتلا ةردقلا .ئراوطلل لوصولا دنع (62%) نم لقأ (ينبولجويالماو ،(ب م) ينتايركلا زينياك ةلتك ،ت – بلقلا يننوبورت ،آ - بلقلا يننوبورت)
 ينبولجويالما لصح .ئراوطلل ضيرلما لوصو نم ينتعاس لوأ للاخ ىرخلأا تامصاولا نم لضفأ اضيأ تناكو (94%) يبلقلا عونلا – ينهدلا ضمحلل طبارلا
ةعاسلا  ينب  تلصح ت  -  بلقلا  يننوبورت  ،(ب م)  ينتايركلا  زينياك  ةلتك  ،آ–  بلقلا  يننوبورتل  سسحتلا  ةمق  .سستح لدعم  ىلعأك  يناثلا  بيترتلا  ىلع�
 بلقلا يننوبورت و يبلقلا عونلا – ينهدلا ضمحلل طبارلا ينتوربلل كرتشلما سايقلا  :ةصلالخا .ئراوطلل ضيرلما لوصو دعب يلاوتلا ىلع 10-8 و ،10 - 4.8 
 .ةداح ةيبلق ةطلج نم نوناعي نيذلا ىضرلما مظعلم ركبلما صيخشتلل ةيفاك ةيعونو ةيساسح وذ ضارعلأا روهظ دعب ىلولاا نامثلا تاعاسلا للاخ ينترم ،آ –
.ىرخلأا تامصاولا ةيقبل ةكرتشلما صوحفلا نم لضفأ تازايتما رفوي كرتشلما صحفلا اذهو
.ةيبلقلا تامش�ا�لا ، يبلقلا ع�نلا – ينهدلا س�محلل طبارلا ينتوبرلا ،ةداح ةيجات ةمزلاتم ،ةداح ةيبلق ةطلج :تاملكلا حاتفم
abstract: Objectives: The objective of this study was to evaluate the diagnostic value of heart-type fatty acid-
binding protein (H-FABP) in patients with acute chest pain and compare it with standard cardiac markers. Methods: 
We undertook a prospective evaluation of 100 consecutive patients admitted with acute chest pain suggestive of 
acute coronary syndromes (ACS). Serum cardiac troponin I (cTnI), cardiac troponin T (cTnT), creatine kinase-
MB (CK-MB) mass, myoglobin, and H-FABP were determined at presentation and 2, 4, 8–10, and 16–24 hours 
after presentation. The main outcome measure was the best sensitivity value within 6 hours after symptom onset. 
Results: H-FABP peak concentration occurred at 8 hours after symptoms onset and was the most sensitive 
early marker with 79.9% and 98% of patients with AMI identified at presentation and 2 hours after presentation 
respectively. The sensitivity of all other cardiac markers (CK-MB mass, cTnI, cTnT, and myoglobin) at presentation 
was < 62%. The negative predictive value of H-FABP (94%) was also superior to other markers within the first 2 
hours of presentation. Myoglobin was the second most sensitive early marker at presentation. Peak sensitivity of 
cTnI, CK-MB mass, and cTnT were present at 4, 8–10, and 8–10 hours respectively after presentation. Conclusion: 
Combined measurement of H-FABP and cTnI on two occasions during the first 8 hours after symptom onset was 
sufficiently sensitive and specific for the early diagnosis of most patients with acute MI and may provide advantages 
over other cardiac marker combinations.
Keywords: Acute myocardial infarction; Acute coronary syndromes; Heart-type fatty acid-binding protein; Cardiac 
markers.
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Chest pain is a non-specific complaint and is the most frequent reason for patients to seek urgent medical attention.1 
A proportion of these patients will be in the process 
of evolving acute myocardial infarction (AMI) and, 
of these, about 25% lack the diagnostic features of 
infarction at presentation despite subsequently 
evolving Q wave infarcts. Current diagnostic 
and triage systems based on clinical history 
and electrocardiogram (ECG) results lack both 
sensitivity and specificity. Between 2 and 10% of 
patients with AMI may be inadvertently discharged 
from accident and emergency (A&E) departments 
leading to serious health and legal consequences. 
Conversely, inappropriate admissions of a large 
number of patients without acute coronary 
syndromes (ACS) will have substantial cost 
implications.2 Cardiac markers are critical in 
making the diagnosis of AMI but, thus far, their role 
has mainly been for retrospective confirmation of 
AMI, 12-24 hours after admission. Creatine kinase 
(CK), CK muscle and brain (CK-MB) and troponins 
lack sufficient precision within the first 6 hours 
of presentation. Myoglobin is an early marker of 
myocardial injury, but has poor specificity.3 
Heart-type fatty acid-binding protein (H-FABP) 
is a novel marker with the potential for the early 
diagnosis of AMI within 6 hours of symptoms onset.4 
Its sensitivity for the diagnosis of AMI is comparable 
with myoglobin; however, the specificity of H-FABP 
for myocardial tissue is significantly better than 
that of myoglobin.5 This early release of H-FABP 
coupled with relative cardiac tissue specificity are 
potential advantages that may be valuable for the 
early diagnosis, triage, and management of patients 
with AMI.6-7 To date, there have been few studies 
comparing the value of these markers for the early 
diagnosis of AMI.8 The aim of the current study 
is to compare the value of H-FABP for the early 
diagnosis of AMI with other cardiac markers such 
as myoglobin, creatine CK-MB mass, serum cardiac 
troponin I (cTnI), and cardiac troponin T (cTnT) in 
a standardised setting.  
Methods
Included in the study, over a seven months period 
in 2002, were 100 consecutive patients with acute 
chest pain admitted within 6 hours of symptoms 
onset through the A&E Department at the Royal 
Infirmary of Edinburgh. Ethical approval was 
obtained from the local ethical committee, the 
Lothian Health Board, Edinburgh, UK. Informed 
consent was obtained from each patient before 
beginning the study. All enrolled patients were 
evaluated by the A&E Department physician. The 
evaluation included a brief history and physical 
examination and a recording of a 12-lead ECG. The 
time of onset of symptoms was carefully recorded 
for each patient at presentation. Five serial blood 
samples beginning at 0 hour (at presentation), 
2 hours, 4 hours, 8–10 hours, and 16–24 hours 
after presentation and cTnI, cTnT, CK-MB mass, 
myoglobin, and H-FABP were measured at each 
time interval. All sequential patients were included 
in this study if they presented within 6 hours after the 
onset of symptoms, and had prolonged ischaemic 
chest pain (≥ 10 minutes in duration) suggestive of 
ACS, with or without ECG changes suggestive of 
ischaemia. Patients were excluded from the study 
if they had: 1) repeated intramuscular injection; 2) 
cardiac arrest at presentation; 3) recent surgery, 
coronary artery bypass graft (CABG) or AMI (< 
1month); 4) any evidence of renal impairment or 
hypothyroidism.
The diagnosis of ST elevation myocardial 
infarction (MI) was based on the revised definition 
of MI and had to include at least two of the 
following three findings:9 1) clinical history of 
prolonged ischaemic chest pain ≥ 30 minutes in 
Advances in knowledge
1. This article broadens our knowledge of the novel marker, heart-type fatty acid binding protein, and its place in the hierarchy system of 
currently available cardiac markers for the very early diagnosis of acute myocardial infarction in patients who present with acute chest 
pain.
 Application to patient care
1.  The information in this article will help health care professionals, who deal directly with patients with acute coronary syndromes, to 
understand better the advantages and limitations of the cardiac marker, heart-type fatty acid-binding protein.
2.  This article offers some recommendations to clinicians on the best combination of cardiac markers for the early diagnosis of ACS and 
when to use them.
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Table 1: Demographic and clinical data of patients in the various study groups. Continuous variables are presented 
as mean ± SD and categorical variables are presented as percentages (in brackets).
Demographic & clinical 
data   
STEMI
Group 1
Non-STEMI
Group 2
UA
Group 3
Angina/atypical
Group 4
P value
No. Patients 45 14 20 21
Age (years) 66.58 ± 11.74 67.36 ± 11.34 67.45 ± 12.31 64.55 ± 9.54 NS
Male
Female
29 (64)
16 (36)
9 (64)
5 (36)
16 (80)
4 (20)
12 (57)
9 (43)
NS
NS
Time to presentation (hrs) 3.57 ± 2.33 5.3 ± 1.28 5.63 ± 1.17 5.0 ± 1.95 NS
Previous history
Angina
UA
AMI
CABG
PCI
6 (13)
6 (13)
1 (2)
6 (13)
10 (22)
9 (64)
3 (21)
6 (43)
5 (36)
4 (29)
10 (50)
3 (15)
10 (50)
2 (10)
2 (10)
15 (71)
4 (19)
8 (38)
5 (23)
3 (14)
< 0.05
NS
NS
NS
NS
risk factors
DM
HTN
Smoker
Ex-smoker
High cholesterol
FHx of IHD
8 (18)
11 (24)
15 (33.3)
4 (8.7)
31 (69)
10 (22.2)
2 (14)
5 (36)
5 (36)
1 (7)
10 (71)
3 (21)
3 (15)
4 (20)
3 (15)
8 (40)
9 (45)
1 (5)
2 (10)
3 (14)
9 (43)
2 (10)
13 (62)
6 (29)
NS
NS
NS
NS
NS
NS
Admission
HR
Systolic BP
Diastolic BP
Typical chest pain
Atypical chest pain
72.97 ± 17.14
136.4 ± 25.93
71.83 ± 16.86
34 (76)
11 (24)
75.56 ± 17.99
133.22 ± 34.26
71.44 ± 18.44
13 (93)
1 (7)
66.92 ± 11.18
151.92 ± 17.93
74.92 ± 11.7
17 (85)
3 (15)
77.0 ± 16.35
134.67 ± 10.49
79.0 ± 13.99
13 (62)
8 (38)
NS
0.024
NS
0.027
NS
ECG changes at admission
Persistent ST elevation
Transient ST elevation
ST depression ±
T wave changes
Other ECG changes
No acute changes
Old Q waves present
39 (87)
-
6 (13)
-
-
-
-
-
3 (21)
9 (64)
-
1 (7)
1 (7)
1 (7)
-
2 (10)
14 (74)
-
1 (5)
2 (10)
5 (25)
-
1 (5)*
3 (14)
-
2 (10)
15 (71)
6 (29)
-
-
-
-
-
-
-
ECG changes at admission:
Persistent ST elevation
Transient ST elevation
ST depression ±
T wave changes
Other ECG changes
No acute changes
Old Q waves present
39 (87)
-
6 (13)
-
-
-
-
3 (21)
9 (64)
-
1 (7)
1 (7)
1 (7)
-
2 (10)
14 (74)
-
1 (5)
2 (10)
5 (25)
-
1 (5)*
3 (14)
-
2 (10)
15 (71)
6 (29)
-
-
-
-
-
-
-
Legend: SD = standard deviation; STEMI = ST elevation myocardial infarction; UA = unstable angina; AMI = acute myocardial infarction;  
CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention; DM = diabetes mellitus; HTN = hypertension; FHX of IHD 
= family history of ischaemic heart disease; HR = heart rate; BP = blood pressure; ST, T, Q, = ST segment, T wave segment, Q wave segment of 
electrocardiogram (ECG); NS = not significant. 
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duration; 2) evolution of typical changes in at 
least two adjacent leads of the ECG, appearance 
of ST segment elevation > 2 mm 0.08 seconds 
after J point persisting for at least 24 hours with or 
without Q waves, defined as ST elevation MI; 3) a 
time-dependent rise in concentration of CK-MB or 
troponins and a subsequent fall. Unstable angina 
was diagnosed when patients had two or more of the 
following criteria without clear-cut ECG changes 
of infarction or cardiac markers (troponins or CK-
MB) elevations diagnostic of AMI: 1) ischaemic 
chest pain ≥ 10 minutes in duration; 2) transient 
ST segment elevation ≥ 1 mm 0.08 seconds after J 
point less than 30 minutes in duration; 3) transient 
or persistent ST segment depression ≥ 1 mm 0.08 
seconds after J point in two adjacent leads; 4) 
symmetrical or asymmetrical T wave inversion ≥ 1 
mm excluding T wave inversion in leads III, AVR, 
and V1 only. Patients were diagnosed as having 
non ST elevation MI if they had one or more of 
the criteria listed above and in addition, they had 
evidence of myocardial necrosis as reflected by 
CK-MB or troponin elevation and a subsequent 
fall. Patients were diagnosed as having atypical 
or anginal chest pain if they had all the following 
criteria: 1) typical or atypical presentation of chest 
pain; 2) none of the above listed ECG changes and 
3) no rise in CK-MB or cTnI.
Patients were divided into four main groups 
for comparison: Group 1 included patients with 
ST elevation MI, the ‘STEMI group’; Group 2 
included patients with non ST elevation MI, the 
‘Non-STEMI’ group; Group 3 included patients 
with unstable angina (UA), the ‘UA group’; Group 
4 included a heterogeneous population of patients 
with mixed medical diagnoses other than the 
above. Patients in Group 4 were referred to as 
‘atypical/anginal chest pain group’. The selected 
diagnostic cut-off concentrations were based on 
receiver operator characteristic (ROC) curve 
analysis [Figures 1A and 1B] between patients with 
MI (STEMI and non-STEMI groups, n = 59) and 
controls (atypical/anginal chest pain group, n = 21 
and healthy blood donor controls, n = 20). These 
cut-off concentrations were CK-MB mass ≥ 5  µg/L 
(sensitivity = 86.3%, specificity = 99%); cTnI ≥ 0.18 
µg/L (sensitivity = 90.8%, specificity = 99%); cTnT 
≥ 0.1 µg/L (sensitivity = 76.4%, specificity = 99%); 
H-FABP ≥ 12.5 µg/L (sensitivity = 91.4%, specificity 
= 86%), and myoglobin ≥ 95 µg/L (sensitivity = 
81.2%, specificity = 99%). 
The laboratory analysis of CTnI, CK-MB 
mass, and myoglobin was done on a Stratus CS 
analyser machine (Dade Behring, Germany), 
using commercially available test materials. The 
coefficients of variations for cTnI were 6.8%, and 
6.7% at concentration range 0.24–0.36 µg/L, and 4.6–
6.9 µg/L respectively. H-FABP was analysed by an 
enzyme linked immunosorbent assay method using 
commercially available assays (Hycult, Cambridge, 
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Figures 1A and B: Receiver operator characteristic (ROC) curves that were used to derive the cut-off concentrations 
for A) the various cardiac markers (blue = CK-MB mass concentrations; green = cTnI concentrations; red = cTnT 
concentrations; black = myoglobin concentrations); and B) H-FABP. See text for sensitivity and specificity values.
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UK). The analytical sensitivity of H-FABP (mean 
± 2SD) was 0.206 ± 0.047 µg/L. The coefficient of 
variation for H-FABP measurements was always 
< 10%. Cardiac-TnT was analysed on Elecsys 2010 
using commercial assays (Roche, Germany). The 
reference ranges quoted by the manufacturer for 
CK-MB mass, cTnI, myoglobin, cTnT, and H-FABP 
assays were validated by assaying the normal ranges 
of 20 healthy blood donor samples (10 males and 10 
females). The mean ± SD concentrations of these 
markers were CK-MB mass = 1.52 ± 0.8 µg/L; cTnI 
= 0.015 ± 0.006 µg/L; myoglobin = 41.5 ± 13.3 µg/L; 
cTnT = 0.011 ± 0.002 µg/L, and H-FABP = 6.86 ± 
2.21 µg/L. 
Statistical analyses were performed using the 
Statistical Package for Social Sciences (SPSSTM, 
Pittsburgh, statistical software, Version 12). 
Variables were expressed as mean ± SD. The 
sensitivity, specificity, positive predictive value 
(PPV), and negative predictive value (NPV) were 
measured for each marker at each time interval after 
presentation and compared. Chi-square tests were 
used to explore the group differences with respect 
to categorical variables. The Kruskal–Wallis H-test 
was conducted to compare continuous variables and 
mean cardiac markers concentrations differences in 
the four groups. Significant results are indicated by 
probability values less than or equal to 0.05. 
Table 2: Sensitivity, specificity, positive predictive value, and negative predictive value of cardiac markers for the 
early diagnosis of AMI within 6 hours after symptoms onset.
Marker(s) Validity Indicator 0 hr 2 hrs 4 hrs 8-10 hrs 16-24 hrs
CK-MB Sensitivity 42 92.2 95.3 95.3 90.6
Specificity 93.75 93.75 93.75 93.75 86.7
PPV 96 98.3 98.4 98.4 96.7
NPV 29 75 83.3 83.3 81.25
CTnI Sensitivity 56 95.3 100 100 100
Specificity 81.25 87.5 93.75 96.88 100
PPV 92.3 96.8 98.46 99.2 100
NPV 31.7 82.35 100 100 100
CTnT Sensitivity 32.8 67.2 85.9 96.9 95.3
Specificity 93.75 93.75 93.75 93.75 93.75
PPV 95.5 97.7 98.2 98.4 98.4
NPV 25.4 41.7 62.5 88.23 83.3
H-FABP Sensitivity 79.7 98 95.3 93.75 75
Specificity 92.3 .93.3 93.75 87.5 93.3
PPV 98 98.4 98.4 98 98
NPV 52 94 83 78 47
Myoglobin Sensitivity 59.4 87.5 89.1 84.38 68.75
Specificity 94 93.75 93.75 93.75 93.75
PPV 97.4 98.24 98.3 98.18 97.8
NPV 38.1 65.22 68.2 60 42.8
Legend: CK-MB = creatine kinase-muscle & brain; PPV = positive predictive value; NPV = negative predictive value; cTnI = serum cardiac 
troponin I; cTnT = serum cardiac troponin T; HFABP = heart-type fatty acid-binding protein
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Panel A: Patients with ST elevation myocardial infarction (STEMI) and non-ST elevation myocardial infarction (Non-
STEMI)
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Panel B: Patients with unstable angina and atypical/anginal pain
Unstable Angina Group
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Legend: CK-MB = creatine kinase-muscle & brain; cTnI = serum cardiac troponin I; H-FABP = heart-type fatty acid-binding protein
Figure 2:  Illustrates the release pattern (time-concentration profile) of the different cardiac markers at each time 
after presentation in patients in the various study groups. The data for cTnT were omitted from the graph because 
they were on a different scale, but were similar to those of cardiac troponin I.
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Results 
Out of 100 consecutive patients presenting with 
acute chest pain, 45 patients (45%) had ST elevation 
MI (Group 1), 14 patients (14 %) had non-STEMI 
(Group 2), 20 patients (20%) had UA (Group 3). 
The last 21 patients (21%) constituted Group 4. 
The demographic and clinical data of the patients 
in these four groups is shown in Table 1. The study 
group consisted of 66% males. The mean age, 
percentage of males/females, the prevalence of 
risk factors, and the prevalence of previous cardiac 
disease (CABG, PCI) were not significantly different 
between the groups. The prevalence of previous 
angina (P < 0.05), systolic blood pressure (P < 0.024) 
and type of chest pain at presentation (P < 0.027) 
were statistically different. Figure 2 illustrates the 
release characteristics of cardiac markers in the 
four groups. For the STEMI group, myoglobin and 
H-FABP were the earliest makers of myocardial 
injury. The peak concentrations of myoglobin and 
H-FABP were reached in samples taken 2 hours 
after presentation (8 hours after symptoms onset). 
The peak concentrations of CK-MB mass and cTnI 
occurred at 8–10 hours after presentation (14–16 
hours after the onset of chest pain). The peak 
concentrations of cTnT occurred at 16–24 hours 
after presentation (24–30 hours after onset of 
symptoms). H-FABP and myoglobin concentrations 
decreased significantly at 16–24 hours, whereas 
CK-MB mass, cTnI, and cTnT were still present in 
high concentrations. For the non-STEMI group, 
H-FABP and myoglobin peak concentrations were 
achieved at 2 hours and the concentrations of these 
markers had decreased to normal levels at 16– 24 
hours after presentation. For CK-MB mass, the 
peak concentration occurred at 8–10 hours. The 
maximum increase in cTnI and cTnT occurred 
late at 16–24 hours. The concentrations of CK-MB 
mass, cTnI, and cTnT were still present in significant 
levels at 16–24 hours. 
Figure 3 is a line chart representation of 
the sensitivity values of cardiac markers for the 
diagnosis of MI in the STEMI only group, n = 45 
patients. H-FABP was the most sensitive marker 
at presentation (75.5%), and it remained elevated 
with a sensitivity of 100% for the next 2–8 hours 
after presentation. H-FABP sensitivity was also 
superior to other markers within the first two 
hours of presentation. Myoglobin and CK-MB mass 
sensitivity were similar in the first 2 hours (93%). 
However, the peak sensitivity of myoglobin (93%) 
and CK-MB mass (100%) were reached at 2 hours, 
and 8–10 hours respectively. Cardiac-TnI reached 
higher sensitivity (97.7%) earlier (2 hours) than 
myoglobin, CK-MB mass, and cTnT. The sensitivity 
of cTnT gradually increased from a low level at 
presentation (24%) to the highest level (100%) at 
8–10 hours after presentation [Figure 3]. 
The overall sensitivity, specificity, PPV, and NPV 
were determined for the whole group (n = 100 
patients). Table 2 shows the percentages of these 
values for the different cardiac markers at each time 
interval after presentation. H-FABP still had the 
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highest sensitivity at presentation (79.9%). Almost 
all patients (98%) with MI were diagnosed within 
2 hours after admission (8 hours after onset of 
symptoms). The specificity of H-FABP at 2 hours was 
93.3%. Compared to other markers, H-FABP had the 
highest NPV (94%) at 2 hours. The PPV of H-FABP 
was also high (98%). Myoglobin had the second 
highest sensitivity at 0 hour (59.4%) rising to 87.5% 
two hours after presentation. The corresponding 
specificity, PPV, and NPV were 93.75%, 98.24%, 
and 65.22% respectively. All other cardiac markers 
had low sensitivities at 0 hr (i.e. at presentation) 
32.8%, 42%, 56% for cTnT, CKMB mass and cTnI 
respectively. The NPV of cardiac markers was also 
low at presentation 25%, 29%, 31.7%, 38.1%, 52% for 
cTnT, CKMB mass, cTnI, myoglobin, and H-FABP 
respectively.  Most of the cardiac markers had high 
PPV (92–100%). The performance of cTnI was better 
than cTnT in terms of overall sensitivity, specificity, 
PPV, and NPV. Reliable sensitivity, specificity, PPV, 
and NPV by CK-MB mass and cTnI were observed 
at 4 hours after presentation. Reliable sensitivity 
(96.9%), specificity (93.75%), PPV (98.4%), and NPV 
(88.23%) of cTnT were evident at 8–10 hours after 
presentation.
Discussion 
In patients presenting with AMI, H-FABP 
appeared to be a reliable cardiac marker indicator 
6 hours after symptom onset, peaked at 8 hours 
and had decreased significantly towards normal 
concentrations by 16-24 hours after presentation. 
These two features of H-FABP, early concentration 
peak following myocardial injury and rapid return 
to normal base line concentration, differentiate 
this marker from the troponins and CK-MB. They 
suggest the potential of H-FABP for early detection 
of myocardial injury and early detection of re-
infarction. The sensitivities of H-FABP (75.5% and 
79.7%) for the detection of AMI, observed within 
the first 6 hours after symptoms onset in this study, 
was in agreement with some previously published 
data.5,10 In our study, H-FABP was the most 
sensitive marker at presentation and within the 
first two hours after presentation (i.e. 8 hours after 
symptom onset) and demonstrated the highest NPV 
(94%). This was consistent with other previously 
published data.11 A study by Alansari et al. showed 
that myoglobin and H-FABP provide little clinical 
value when measured on admission in patients 
presenting with chest pain.8 Most of the standard 
cardiac markers in Alansari’s study had limited 
diagnostic value at presentation. The overall NPV of 
all cardiac markers was low < 52% within the first 6 
hours after symptom onset. The sensitivity of these 
markers for the early diagnosis of AMI was < 62%. 
Bakker et al. reported low sensitivity (< 64%) and 
low NPV of routine cardiac markers CK-MB mass, 
cTnT, myoglobin, CK-MB activity, and CK to allow 
early exclusion of AMI.12 
This study highlights two important facts: 
1) H-FABP was more sensitive than myoglobin 
and 2) H-FABP had higher NPV than myoglobin. 
High sensitivity is essential for the early ‘rule in’ of 
patients with AMI, and high NPV is important for 
the early ‘rule out’ of AMI, since more than 90% of 
patients who present with acute chest pain to an 
A&E department do not have AMI. This superiority 
of H-FABP over myoglobin may be attributable to 
the fact that 1) the myoglobin content of skeletal 
muscle is twice that of the heart (hence interference 
from skeletal muscle injury i.e. less specific) whereas 
the H-FABP content of skeletal muscles is only 10–
50% of that of the heart and 2) the normal plasma 
concentration of H-FABP (< 5 µg/L) is 10–15 fold 
lower than that of myoglobin (20–80 µg/L).5 Hence, 
the differing features of myoglobin and H-FABP 
allow the use of lower, but more discriminate, cut-
off concentrations of H-FABP thus improving the 
sensitivity. The limitation of the enzyme-linked 
immunosorbent assay (ELISA) method, which 
produces results in around 90 minutes, could be 
overcome by using the new rapid bed-side H-FABP 
tests.13 However, as it is solely excreted by the kidney, 
this cardiac marker has limitations in patients with 
renal impairment and skeletal muscle injury.14
Conclusion
The main conclusions of this study are, first, that 
H-FABP was superior to myoglobin (and other 
markers) for the early diagnosis of AMI within 6 
hours after symptom onset. Second, the diagnostic 
window for H-FABP is relatively prolonged (up to 
14 hours after symptom onset). This diagnostic 
window provides sufficient opportunity for the 
detection of AMI and initiation of appropriate 
therapy. Third, cTnI, as measured on the Stratus CS 
machine, was highly sensitive supporting its use for 
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the early detection of patients with AMI. Fourth, 
measurement of H-FABP and cTnI at two intervals 
during the first 8 hours after symptom onset was 
sufficiently sensitive and specific for the early 
diagnosis of most patients with AMI. We propose 
an alternative: that H-FABP should be combined 
with a specific marker like cTnI. The combination 
of H-FABP and cTnI improves specificity for a 
definitive diagnosis of AMI. We also propose that 
this combination should be tested in a larger-scale 
study and, if the current findings are confirmed, 
H-FABP and cTnI may constitute the standard 
combination for early diagnosis of MI.
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